Department of Nephrology, Monash Health, Melbourne, Victoria, Australia.
Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.
JAMA Netw Open. 2024 Aug 1;7(8):e2430913. doi: 10.1001/jamanetworkopen.2024.30913.
Transplant recipients experience high rates of adverse pregnancy outcomes; however, contemporary estimates of the association between solid organ transplantation and adverse pregnancy outcomes are lacking.
To evaluate the association between solid organ transplantation and adverse pregnancy outcomes and to quantify the incidence of allograft rejection and allograft loss during pregnancy.
PubMed/MEDLINE, EMBASE and Scopus databases were searched from January 1, 2000, to June 20, 2024, and reference lists were manually reviewed.
Cohort and case-control studies that reported at least 1 adverse pregnancy outcome in pregnant women with solid organ transplantation vs without solid organ transplant or studies that reported allograft outcomes in pregnant women with solid organ transplantation were included following independent dual review of abstracts and full-text articles.
Two investigators abstracted data and independently appraised risk of bias using the Newcastle Ottawa Scale. A random-effects model was used to calculate overall pooled estimates using the DerSimonian-Laird estimator. Reporting followed the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline.
Primary pregnancy outcomes were preeclampsia, preterm birth (<37 weeks), and low birth weight (<2500 g). Secondary pregnancy outcomes were live birth rate, gestation, very preterm birth (<32 weeks), very low birth weight (<1500 g), and cesarean delivery. Allograft outcomes were allograft loss and rejection during pregnancy.
Data from 22 studies and 93 565 343 pregnancies (4786 pregnancies in solid organ transplant recipients) were included; 14 studies reported adverse pregnancy outcomes, and 13 studies provided data for allograft outcomes. Pregnancies in organ transplant recipients were associated with significantly increased risk of preeclampsia (adjusted odds ratio [aOR], 5.83 [95% CI, 3.45-9.87]; I2 = 77.4%), preterm birth (aOR, 6.65 [95% CI, 4.09-12.83]; I2 = 81.8%), and low birth weight (aOR, 6.51 [95% CI, 2.85-14.88]; I2 = 90.6%). The incidence of acute allograft rejection was 2.39% (95% CI, 1.20%-3.96%; I2 = 68.5%), and the incidence of allograft loss during pregnancy was 1.55% (95% CI, 0.05%-4.44%; I2 = 69.2%).
In this systematic review and meta-analysis, pregnancies in recipients of a solid organ transplant were associated with a 4 to 6 times increased risk of preeclampsia, preterm birth, and low birth weight during pregnancy. There was a low overall risk of graft rejection or loss during pregnancy.
移植受者经历不良妊娠结局的发生率较高;然而,目前缺乏关于实体器官移植与不良妊娠结局之间关联的最新估计。
评估实体器官移植与不良妊娠结局之间的关联,并量化妊娠期间同种异体移植物排斥和同种异体移植物丢失的发生率。
从 2000 年 1 月 1 日至 2024 年 6 月 20 日,对 PubMed/MEDLINE、EMBASE 和 Scopus 数据库进行了检索,并手动审查了参考文献列表。
纳入了至少报告了 1 例实体器官移植孕妇与未接受实体器官移植孕妇不良妊娠结局的队列和病例对照研究,或报告了实体器官移植孕妇同种异体移植物结局的研究。经过对摘要和全文文章的独立双重审查后,这些研究被纳入。
两名调查员提取数据,并使用纽卡斯尔-渥太华量表独立评估偏倚风险。使用 DerSimonian-Laird 估计值的随机效应模型计算总体汇总估计值。报告遵循观察性研究的荟萃分析 (MOOSE) 报告指南。
主要妊娠结局是子痫前期、早产(<37 周)和低出生体重(<2500g)。次要妊娠结局是活产率、孕龄、极早产(<32 周)、极低出生体重(<1500g)和剖宫产。同种异体移植物结局是妊娠期间的同种异体移植物丢失和排斥。
纳入了 22 项研究和 93565343 例妊娠(4786 例在实体器官移植受者中)的数据;14 项研究报告了不良妊娠结局,13 项研究提供了同种异体移植物结局的数据。器官移植受者的妊娠与子痫前期(调整后的优势比[OR],5.83[95%CI,3.45-9.87];I2=77.4%)、早产(调整后的 OR,6.65[95%CI,4.09-12.83];I2=81.8%)和低出生体重(调整后的 OR,6.51[95%CI,2.85-14.88];I2=90.6%)的风险显著增加相关。急性同种异体移植物排斥的发生率为 2.39%(95%CI,1.20%-3.96%;I2=68.5%),妊娠期间同种异体移植物丢失的发生率为 1.55%(95%CI,0.05%-4.44%;I2=69.2%)。
在这项系统评价和荟萃分析中,实体器官移植受者的妊娠与妊娠期间子痫前期、早产和低出生体重的风险增加 4 至 6 倍相关。总体来看,同种异体移植物排斥或丢失的风险较低。